15例多发性骨髓瘤应用硼替佐米为主化疗方案治疗的临床不良反应分析  

Clinical analysis of 15 patients about adverse effects in the treatment of multiple myeloma with bortezomib combined regimen

作　　者：王志芳[1] 孟祥玲[1] 赵恩锋[1] 

机构地区：[1]沧州中西医结合医院肿瘤血液内科,河北沧州061000

出　　处：《现代肿瘤医学》2013年第3期641-643,共3页Journal of Modern Oncology

摘　　要：目的:观察硼替佐米为主化疗方案治疗多发性骨髓瘤(MM)的毒副作用及处理对策。方法:回顾分析15例含硼替佐米为主化疗方案治疗MM的临床资料,按国际肿瘤组织的毒性判定标准评价不良反应。结果:胃肠道反应8例,白细胞减少9例,血小板减少12例,周围神经病变症状6例,感染11例,经对症、暂时停药后大部分有所改善,少数为不可逆的改变;出现少见不良反应急性心功能不全1例。结论:硼替佐米为主的化疗方案治疗MM的毒副作用患者基本可耐受,但也有少见的及不可逆的不良反应发生,应引起重视。Objective：To summarize the adverse effects and treatments of bortezomib combined regimen in the treatment of multiple myeloma（MM）. Methods： Data of 15 patients with multiple myeloma diagnosed by NCICTCAE （3.0 version） were retrospectively analyzed. Results： The incidences of main drug related toxicities were 53% for gastrointestinal reactions,60% for leukopenia, 80% for thrombocytopenia,40% for peripheral neuropathy and 73% for infection. The adverse effects could be relieved by symptomatic treatment or suspended chemotherapy,few couldnt be relieved. There was one case with acute cardiac insufficiency. Conclusion： The bortezomib combined regimen could be tolerable and safe in most MM patients, but attention should be paled to some rare adverse effects.

关 键 词：硼替佐米 多发性骨髓瘤 不良反应 

分 类 号：R733.3[医药卫生—肿瘤]